BioPorto (NASDAQ COPENHAG:BIOPOR) A/S has appointed Nis Kruse as Executive Vice President of Strategic Partnerships and General Manager of EMEA & APAC as the company gears up for the prospective global launch of its neutrophil gelatinase-associated lipocalin (NGAL) tests.
“We are preparing for the prospective global launch of NGAL tests, having submitted our De Novo application to the US Food and Drug Administration to aid in identifying pediatric patients at risk of moderate to severe acute kidney injury,” said Tony Pare, BioPorto (NASDAQ COPENHAG:BIOPOR)’s CEO.
“Nis’ experience in strategic partnership development, distributor management, and building commercial teams will be a welcome addition to the BioPorto executive team,” he added.
READ: BioPorto submits milestone De Novo application to US Food and Drug Administration for its NGAL test
Kruse most recently served as SVP and chief commercial officer at SSI Diagnostica A/S, an in vitro diagnostics company focusing on infectious diseases, having delivered substantial top-line growth in the company during the pandemic.
Previously, he operated in a US-based position as Executive Director, Global Precision Medicine at Merck & Co, where he was responsible for commercial diagnostic strategy and commercial partner management.
“I am excited to join BioPorto at this key juncture in advancing NGAL tests into routine clinical use,” Kruse said.
Kruse will also serve as site leader for the Hellerup, Denmark office.
Contact Jeremy at jeremy@proactiveinvestors.com